Adverum Biotechnologies Inc (ADVM)


Stock Price Forecast

March 22, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Adverum Biotechnologies Inc chart...

About the Company

Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema.

CEO

Leone Patterson

Exchange

NASDAQ

Website

adverum.com

$99M

Total Revenue

188

Employees

$78M

Market Capitalization

-0.48

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ADVM News

Adverum Biotechnologies Inc.

23d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Data-Based Analysis Of Adverum Biotechnologies Inc. (ADVM)

11d ago, source:

Adverum Biotechnologies Inc. (NASDAQ:ADVM) concluded the trading at $0.79 on Friday, March 10 with a fall of -2.47% from its closing price on previous day. Taking a look at stock we notice that its ...

Adverum Biotechnologies to Present at Upcoming Investor Conferences

23d ago, source: Yahoo Finance

REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for ...

Adverum Biotechn (ADVM) Earnings Dates & Reports

3d ago, source: Investing

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023

on MSN ago, source:

Hallum upgraded the previous rating for Carrols Restaurant Group Inc (NASDAQ:TAST) from Hold to Buy. In the fourth quarter, Carrols Restaurant Group showed an EPS of $0.05, compared to $0.15 from the ...

Is Curative Biotechnology Inc (CUBT) Stock a Good Investment?

13d ago, source: American Association of Individual Investors

Learn more about Curative Biotechnology Inc's (CUBT) stock grades for Momentum and Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.

Q4 2022 Gracell Biotechnologies Inc Earnings Call

8d ago, source: Yahoo! Sports

Wei Cao; Founder, Chairman & CEO; Gracell Biotechnologies Inc. Wendy Li; Chief Medical Officer; Gracell Biotechnologies Inc. Yili Xie; CFO; Gracell Biotechnologies Inc. Carly Nicole Kenselaar ...

Adverum Biotechnologies Inc (ADVM)

5d ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Adverum Biotechnologies to Present at Upcoming Investor Conferences

23d ago, source: MarketWatch

Feb 27, 2023 (GLOBE NEWSWIRE via COMTEX) -- REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish ...

ADVM Adverum Biotechnologies, Inc.

28d ago, source: Seeking Alpha

The chart has 1 X axis displaying Time. Data ranges from 2022-02-22 00:00:00 to 2023-02-23 16:55:49. The chart has 1 Y axis displaying values. Data ranges from -58.46 to 34.62.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...